Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Depreciation & Amortization (CF) (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $723000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 1.69% to $723000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 30.23% decrease, with the full-year FY2025 number at $2.9 million, down 29.27% from a year prior.
  • Depreciation & Amortization (CF) was $723000.0 for Q4 2025 at TScan Therapeutics, down from $767000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.5 million in Q1 2023 to a low of $469000.0 in Q1 2021.
  • A 5-year average of $1.0 million and a median of $1.1 million in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): surged 205.2% in 2021, then tumbled 45.93% in 2025.
  • TScan Therapeutics' Depreciation & Amortization (CF) stood at $1.1 million in 2021, then grew by 29.95% to $1.5 million in 2022, then fell by 13.75% to $1.3 million in 2023, then plummeted by 44.45% to $711000.0 in 2024, then grew by 1.69% to $723000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Depreciation & Amortization (CF) are $723000.0 (Q4 2025), $767000.0 (Q3 2025), and $698000.0 (Q2 2025).